FilingReader Intelligence
Tiantan Bio subsidiary starts phase III neuropathy drug trial
July 17, 2025 at 08:09 AM UTC•By FilingReader AI
Chengdu Rong Sheng Pharmaceuticals, a subsidiary of Beijing Tiantan Biological Products, announced Phase III clinical trials for its intravenous human immunoglobulin product targeting chronic inflammatory demyelinating polyneuropathy.
Development has involved an investment of 18.5m yuan. This is the first intravenous human immunoglobulin product in China approved for clinical research for this condition.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600161•Shanghai Stock Exchange
Pharmaceuticals
News Alerts
Get instant email alerts when Beijing Tiantan Biological Products Corp publishes news
Free account required • Unsubscribe anytime